Page last updated: 2024-12-10

dipalmitoylphosphatidylserine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID3081382
CHEBI ID191300
SCHEMBL ID2733430
MeSH IDM0116327

Synonyms (17)

Synonym
l-serine, 2,3-bis((1-oxohexadecyl)oxy)propyl hydrogen phosphate (ester)
unii-he802c2tfr
he802c2tfr ,
1,2-dipalmitoyl-rac-glycero-3-phospho-l-serine, ~98%
CHEBI:191300
3036-82-6
dipalmitoylphosphatidylserine
(2s)-2-amino-3-[2,3-di(hexadecanoyloxy)propoxy-hydroxyphosphoryl]oxypropanoic acid
SCHEMBL2733430
4,6,10-trioxa-5-phosphahexacosanoic acid, 2-amino-5-hydroxy-11-oxo-8-((1-oxohexadecyl)oxy)-, 5-oxide, (2s)-
dl-.alpha.-dipalmitoylphosphatidylserine
dl-.alpha.-dipalmitoyl phosphatidyl-l-serine
Q27896139
dl-alpha-dipalmitoylphosphatidylserine
o-((2,3-bis(palmitoyloxy)propoxy)(hydroxy)phosphoryl)-l-serine
4,6,10-trioxa-5-phosphahexacosanoic acid, 2-amino-5-hydroxy-11-oxo-8-[(1-oxohexadecyl)oxy]-, 5-oxide, (2s)-
DTXSID201307601
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
phosphatidyl-L-serineA class of aminophospholipids in which a phosphatidyl group is esterified to the hydroxy group of serine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (63)

PathwayProteinsCompounds
Phospholipid Biosynthesis2529
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:0/16:1(9Z))1322
phospholipid biosynthesis CL(15:0cyclo/15:0cyclo/16:1(9Z)/16:0)1121
phospholipid biosynthesis CL(15:0cyclo/16:0/15:0cyclo/16:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/16:0/16:0/16:0)1121
phospholipid biosynthesis CL(15:0cyclo/16:0/16:1(9Z)/15:0cyclo)1120
phospholipid biosynthesis CL(15:0cyclo/16:0/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(15:0cyclo/16:0/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:0/16:1(9Z))1121
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/16:0)1323
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/16:1(9Z)/16:1(9Z))1324
phospholipid biosynthesis CL(15:0cyclo/16:1(9Z)/18:1(9Z)/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/16:0/18:1(9Z))1120
phospholipid biosynthesis CL(15:0cyclo/18:1(9Z)/18:1(9Z)/16:0)1120
phospholipid biosynthesis CL(16:0/15:0cyclo/15:0cyclo/16:1(9Z))1120
phospholipid biosynthesis CL(16:0/15:0cyclo/16:0/16:0)1121
phospholipid biosynthesis CL(16:0/15:0cyclo/16:1(9Z)/15:0cyclo)1121
phospholipid biosynthesis CL(16:0/15:0cyclo/16:1(9Z)/16:1(9Z))1323
phospholipid biosynthesis CL(16:0/15:0cyclo/18:1(9Z)/18:1(9Z))1121
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:0/16:1(9Z))1323
phospholipid biosynthesis CL(16:1(9Z)/15:0cyclo/16:1(9Z)/16:0)1323
phospholipid biosynthesis (CL(18:1(9Z)/16:0/17:0cycw7c/16:0))917
Lysolipid incorporation into Mitochondria PC(16:0/16:0)515
Lysolipid Incorporation into ER PC(16:0/16:0)1024
Phosphatidylcholine Biosynthesis PC(16:0/16:0)620
Phosphatidylethanolamine Biosynthesis PE(16:0/16:0)516
Phosphatidylcholine/Phosphatidylethanolamine Biosynthesis PC(16:0/16:0) | PE(16:0/16:0)617
Phospholipid Biosynthesis CL(16:0/16:0/14:0/14:0)323
Phospholipid Biosynthesis CL(16:0/16:0/14:0/16:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/14:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/14:0/18:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/14:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:0/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:0/18:1(9Z))326
Phospholipid Biosynthesis CL(16:0/16:0/16:0/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/16:0)325
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/16:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/16:0)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/17:0cycw7/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/16:0)326
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/16:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/18:1(9Z))325
Phospholipid Biosynthesis CL(16:0/16:0/18:1(9Z)/19:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/14:0)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/15:0cycw5)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/16:0)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/16:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/17:0cycw7)322
Phospholipid Biosynthesis CL(16:0/16:0/19:0cycw7/18:1(9Z))322
Phospholipid Biosynthesis CL(16:0/16:0/16:0/16:0)324

Research

Studies (105)

TimeframeStudies, This Drug (%)All Drugs %
pre-19903 (2.86)18.7374
1990's27 (25.71)18.2507
2000's40 (38.10)29.6817
2010's31 (29.52)24.3611
2020's4 (3.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 15.94

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index15.94 (24.57)
Research Supply Index4.69 (2.92)
Research Growth Index5.45 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (15.94)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.93%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other107 (99.07%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]